Welcome to DailyUpdates Technology Channel: Dedicated to Biologics, Cell & Gene Therapies and Novel Approaches to Vaccines, Drug Delivery, Diagnostics & Drug Development - the R&D community's bulletin of breaking research, clinical trials and drug development news. This page will update each day. You have access for 2 more day(s). To receive DailyUpdates by e-mail register here


PubMed DailyUpdates: Breaking Scientific Publications for the Drug Discovery Community

DailyUpdates by e-mail - the publication tracker for the drug discovery community

Technology Channel: Dedicated to Biologics, Cell & Gene Therapies and Novel Approaches to Vaccines, Drug Delivery, Diagnostics & Drug Development



If this icon appears after any of our listed articles, the author is able to provide reprints. Articles denoted by an Licensing Op. icon describe data relevant to licensing opportunities. The report icon, , links through to full analyses relating to pharmaceutical/market developments relating to this work

Facebook

Today's journal articles

No journal articles today

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

Reduced Immunogenicity Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma

Nivolumab Plus Radiotherapy in Advanced Melanoma

Siltuximab in Schizophrenia

A Study of Once-Weekly Emicizumab in Children and Adolescents With Hemophilia A and Factor VIII (FVIII) Inhibitors

Previous Journal Entries

High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.

A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.

Intranasal Immunization with DOTAP Cationic Liposomes Combined with DC-Cholesterol Induces Potent Antigen-Specific Mucosal and Systemic Immune Responses in Mice.

IL-23, Independent of IL-17 and IL-22, Drives Neutrophil Recruitment and Innate Inflammation During Clostridium difficile Colitis in Mice.

Anti-IL-20 Monoclonal Antibody Suppresses Prostate Cancer Growth and Bone Osteolysis in Murine Models.

Cost-Effectiveness of RAS Screening before Monoclonal Antibodies Therapy in Metastatic Colorectal Cancer Based on FIRE3 Study.

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

The efficacy and safety of endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma.

Generation and Characterisation of ALX-0171, a potent novel therapeutic Nanobody® for the treatment of Respiratory Syncytial Virus infection.

Recombinant adenovirus encoding NLRP3 RNAi attenuate inflammation and brain injury after intracerebral hemorrhage.

90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.

Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study.

The use of an IL1-receptor antagonist to prevent the progression of tendinopathy in a rat model.

A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: results of a phase II study.

Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery.

MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis.

A novel delivery platform based on Bacteriophage MS2 virus-like particles.

MiR-140-3p suppressed cell growth and invasion by downregulating the expression of ATP8A1 in non-small cell lung cancer.

Encapsulation in a rapid-release liposomal formulation enhances the anti-tumor efficacy of pemetrexed in a murine solid mesothelioma-xenograft model.

Cutting Edge: IL-25 Targets Dendritic Cells To Attract IL-9-Producing T Cells in Acute Allergic Lung Inflammation.

Today's News Items

Sun Pharma and Almirall enter into a License Agreement for Tildrakizumab in Europe for Psoriasis

Caladrius Biosciences Receives FDA Fast Track Designation for CLBS03 to Treat Recent Onset Type 1 Diabetes

Merck to Provide Provantage® End-to-End Development and Manufacturing Services to Y-mAbs for Lead Antibody Compound

SHIRE ANNOUNCES FDA APPROVAL OF ADYNOVATE WITH BAXJECT III RECONSTITUTION SYSTEM

Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma

Pluristem Receives Positive Feedback from FDA and Gears Up for Phase III Trial of PLX-PAD in Critical Limb Ischemia

Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR® T-cell Therapy in Myxoid Round Cell Liposarcoma

NICE draft guidance recommends new drug for people with ankylosing spondylitis

DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401

Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer

GSK in-licenses anti-IL-33R monoclonal antibody for severe asthma from Janssen

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy - See more at: http://www.merck.com/newsroom/#News

Merck’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1 - See more at: http://www.merck.com/newsroom/#News

MorphoSys Successfully Completes Safety Run-in of MOR208 in L-MIND Combination Study in Patients with DLBCL

Neon Therapeutics Announces FDA Acceptance of Investigational New Drug Application for Cancer Vaccine NEO­-PV­-01

Training Courses & Meetings

No events listed

Previous News Items

Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial’s Safety Review Committee

Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab

Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA

Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency

CHMP Issues Positive Opinion for ORENCIA® (abatacept) in the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis not Previously Treated with Methotrexate in the EU

AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen

Merrimack Announces ONIVYDE® Regimen Receives Positive CHMP Opinion in European Union

Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia and Rare Bleeding Disorders

Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA

Janssen Announces Clinical Collaboration with Bristol-Myers Squibb to Evaluate Immuno-oncology Combination in Lung Cancer

Daratumumab (DARZALEX®) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Use in Combination with Standard of Care Regimens for Patients with Multiple Myeloma

GamaMabs Pharma starts phase Ia/Ib study of first-in-class monoclonal antibody GM102 in advanced gynecological cancer

Sun Pharma and Almirall enter into a License Agreement for Tildrakizumab in Europe for Psoriasis